SAN DIEGO, March 2, 2016 /PRNewswire/ -- Today, DermTech, Inc., a privately held dermatology company commercializing non-invasive gene expression tests for skin cancer, announced a sales and marketing collaboration with Dermpath Diagnostics. Dermpath Diagnostics is a business of Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic information services. Dermpath Diagnostics is exclusively focused on providing exceptional dermatopathology services to referring physicians and patients. Under the arrangement, Dermpath Diagnostics will provide specialty dermatology representatives in up to 10 regional territories across the United States to assist DermTech in marketing its Pigmented Lesion Assay (PLA) for assessing melanocytic lesions (nevi and melanoma) via gene expression.
"We are excited to commence this effort with Dermpath Diagnostics, a recognized leader in dermatopathology services. This collaboration will significantly expand our ability to offer the PLA to dermatologists in the U.S," said Sarah Dennison, Vice President of Marketing.
E. Michael Kramer, M.D., Vice President, Dermatopathology, Dermpath Diagnostics commented, "We are pleased to align with DermTech in offering their innovative PLA and to further our mission to provide comprehensive dermatopathology services to the medical community."
DermTech is a commercial stage molecular dermatology company developing non-invasive gene expression tests to aid the clinical diagnosis of skin cancer and other skin conditions. DermTech operates a CLIA licensed laboratory located in the company's La Jolla, CA headquarters. DermTech's technology allows the analysis of skin biopsy samples collected non-invasively using an adhesive patch. DermTech provides highly accurate, objective information to the physicians to improve care and reduce costs. Current dermatologic diagnosis is primarily based on subjective visual pattern recognition that is prone to error and results in a substantial number of unnecessary surgical procedures. For additional information visit: www.dermtech.com.
About Dermpath Diagnostics
Dermpath Diagnostics is exclusively focused on providing exceptional dermatopathology services to patients and physicians. Dermpath's commitment to dermatopathology is backed by an unrivaled team of over 85 board-certified dermatopathologists, advanced diagnostic technologies and a proficient support team dedicated to serving clinicians and patients. Dermpath's mission is to provide accurate, clear and prompt diagnoses. Through the development of strong consultative relationships with each of Dermpath Diagnostic's referring clinicians, Dermpath Diagnostics is able to provide the best possible care for every patient. For additional information visit: www.dermpathdiagnostics.com.
Media Contact: Sarah Dennison, MBA VP of Marketing (858) 450-4222 email@example.com
SOURCE DermTech, Inc.